oAlert.pl

Medicines & supplements – Current GIS Alerts 2026

Found 735 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Recalled product: Mebelin

Mebelin

GIF Medium 26.06.2023

Due to the reduced values of active substance release in the product, the risk to patient health resulting from decreased drug efficacy cannot be excluded. Potential effects: lack of treatment efficacy, possible worsening of disease symptoms.

Recalled product: PALIFREN LONG

PALIFREN LONG

GIF Medium 16.06.2023

A reduced content of the active substance paliperidone palmitate and an increased particle size compared to requirements were found, which may lead to reduced medicinal efficacy and a risk to patient health. Potential effects: reduced treatment efficacy, worsening of disease symptoms.

Recalled product: Duracef

Duracef

GIF Medium 14.06.2023

Testing showed a lower value of cefadroxil release within 30 minutes, so a risk to patient health due to lack of drug efficacy cannot be excluded. Potential effects: lack of treatment effectiveness, possible disease complications.

Recalled product: APAP dla dzieci FORTE

APAP dla dzieci FORTE

GIF Medium 26.05.2023

The suspension in the bottle contained gas bubbles, was foamed, had increased volume, and in several cases was non-uniform and separated into layers, which may indicate a significant quality defect of the medicine. Potential effects: incorrect dosing, reduced effectiveness, possible adverse reactions.

Recalled product: Tirosint Sol

Tirosint Sol

GIF High 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: lack of efficacy in treating thyroid disorders, worsening of health status, possible complications of concomitant diseases.

Recalled product: Tirosint Sol

Tirosint Sol

GIF High 27.04.2023

A probability of reduced content of the active substance – levothyroxine sodium – was identified in some batches, which may lead to insufficient treatment efficacy. Potential effects: lack of thyroid disease control, complications, worsened well-being.

Recalled product: Tirosint Sol

Tirosint Sol

GIF High 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health from decreased drug effectiveness cannot be excluded. Potential effects: lack of treatment efficacy, complications of the underlying disease.

Recalled product: Tirosint Sol

Tirosint Sol

GIF High 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, possible worsening of thyroid disease symptoms.

Recalled product: Tirosint Sol

Tirosint Sol

GIF High 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: ineffective treatment, worsening of disease symptoms, complications resulting from thyroid hormone deficiency.

Recalled product: Tirosint Sol

Tirosint Sol

GIF Medium 27.04.2023

A probability of reduced content of the active substance – levothyroxine sodium – was identified, which prevents guaranteeing proper medicinal quality and may lead to reduced therapeutic efficacy. Potential effects: reduced treatment effectiveness, risk of exacerbation of thyroid disease symptoms.

Recalled product: Tirosint Sol

Tirosint Sol

GIF Medium 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment effectiveness, worsening of disease symptoms.

Recalled product: Tirosint Sol

Tirosint Sol

GIF Medium 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: lack of treatment efficacy, disease worsening.

Recalled product: Tirosint Sol

Tirosint Sol

GIF Medium 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, disease complications, deterioration of health status.

Recalled product: Tirosint Sol

Tirosint Sol

GIF Medium 27.04.2023

Due to the probability of a reduced content of the active substance in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: ineffective treatment of hypothyroidism, worsening of disease symptoms.

Recalled product: Tirosint Sol

Tirosint Sol

GIF Medium 27.04.2023

Due to the probability of reduced active substance content in the product, a risk to patient health resulting from decreased efficacy of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, possible worsening of thyroid disease control.

Recalled product: Sirdalud MR

Sirdalud MR

GIF High 07.04.2023

It was found that batch KDF58 does not meet the requirements for the mean value of tizanidine hydrochloride release at 2 hours, and the cause of this deviation is unknown, so the impact on product quality, safety of use and the risk to patients’ health cannot be predicted. Potential effects: overdose or insufficient drug effect, treatment complications.

Recalled product: Vectibix

Vectibix

GIF Critical 05.04.2023

The quality defect could cause leakage and loss of sterility of the medicine, creating a risk of microbial contamination and serious adverse reactions, posing a threat to the patient’s health and life. Potential effects: infection, severe complications, sepsis, life-threatening conditions.

Recalled product: Elocom

Elocom

GIF High 29.03.2023

A risk was identified that Elocom cream 1mg/g was marketed in outer cartons intended for the ointment, resulting in an incorrect description of the dosage form and uncertainty for patients. Potential effects: misuse of the medicine, lack of efficacy or increased adverse reactions.

Recalled product: Elocom

Elocom

GIF High 29.03.2023

A risk was identified of placing on the market Elocom 1 mg/g cream packed in outer cartons for the “ointment” dosage form, causing labeling inconsistent with the contents and potentially misleading patients. Potential effects: improper use of the medicine, lack of expected efficacy, skin complications.

Recalled product: Melisa Fix

Melisa Fix

GIF Medium 24.03.2023

The Chief Pharmaceutical Inspector states that the quality defect does not allow exclusion of the possibility of exceeding the acceptable daily intake limit of Stevia rebaudiana. Potential effects: adverse effects related to excessive intake, metabolic disturbances, lack of safe use.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.